Award4

Akari Therapeutics Plc

Total Value

$777.8K

Filing Date

Oct 14, 2026

1 transactions

Trade Summary

On Oct 12, 2026, Vat-Ho Vatnak, Chief Business Officer, reported $777.8K of Akari Therapeutics Plc (AKTX) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Reported prices ranged from $8.94. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Vat-Ho Vatnak
Role: Chief Business Officer
Location: TAMPA, FL

Filing Details

Filing Date: Oct 14, 2026
Transaction Date: Oct 12, 2026
Accession Number: 0001493152-26-047058
Form Type: 4

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Oct 12, 2026	AKTX derivative	87,000	$8.94	Grant/Award	$777.8K

Want live alerts when Vat-Ho Vatnak trades again?

Download Insider Trades to track AKTX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)On October 5, 2026 (the "Grant Date"), the reporting person was granted an option to purchase 87,000 ADSs. This option grant is subject to forfeiture and cancellation if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan is not obtained. The option will vest with respect to 25% on the 12-month anniversary of the Grant Date, with the remainder vesting in equal monthly installments over the next 36 months until fully vested on the 4-year anniversary of the Grant Date, subject to the grantee's continued service with the Company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vat-Ho Vatnak

(Last)

(First)

(Middle)

C/O AKARI THERAPEUTICS PLC

401 EAST JACKSON STREET, SUITE 3300

(Street)

TAMPA

33602

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.94	10/12/2026		A		87,000		⁽¹⁾	10/05/2036	American Depositary Shares representing Ordinary Shares	87,000	$0	87,000	D

Explanation of Responses:

1. On October 5, 2026 (the "Grant Date"), the reporting person was granted an option to purchase 87,000 ADSs. This option grant is subject to forfeiture and cancellation if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan is not obtained. The option will vest with respect to 25% on the 12-month anniversary of the Grant Date, with the remainder vesting in equal monthly installments over the next 36 months until fully vested on the 4-year anniversary of the Grant Date, subject to the grantee's continued service with the Company.

	/s/ Abizer Gaslightwala, as Attorney-in-Fact	10/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001493152-26-047058.

Akari Therapeutics Plc

Trade Summary

Company Information

Insider Information

Filing Details

Derivative Transactions

Want live alerts when Vat-Ho Vatnak trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4